Compare QNST & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNST | ACRS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 868.5M |
| IPO Year | 2009 | 2015 |
| Metric | QNST | ACRS |
|---|---|---|
| Price | $18.30 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $24.75 | $10.20 |
| AVG Volume (30 Days) | 812.2K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1650.00 | 69.01 |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $282,140,000.00 | $1,683,000.00 |
| Revenue This Year | $18.59 | N/A |
| Revenue Next Year | $14.80 | $4.24 |
| P/E Ratio | $13.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.29 | $1.74 |
| 52 Week High | $22.29 | $6.60 |
| Indicator | QNST | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 45.15 |
| Support Level | $11.08 | $4.13 |
| Resistance Level | $21.23 | $5.87 |
| Average True Range (ATR) | 0.77 | 0.34 |
| MACD | -0.28 | -0.11 |
| Stochastic Oscillator | 31.02 | 32.87 |
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. The company operates as one reportable segment. The company generates majority of revenue from United States. The company's products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and Cloud Control Media.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.